Novartis drug for muscle-wasting condition gets FDA breakthrough designation

Novartis (NVS +2.4%) has received FDA breakthrough therapy designation for its BYM338 (bimagrumab) drug for treating sufferers of sporadic inclusion body myositis (sIBM), a rare yet potentially fatal muscle-wasting condition.

If eventually authorized, BYM338 has the potential to become the first treatment for sIBM.

BYM338 is the third Novartis drug this year to obtain the FDA's breakthrough designation. The company developed it with Morphosys (MPSYF.PK).

Patients with sIBM can gradually lose their ability to walk, experience falls and injuries, lose hand function, and have swallowing difficulties. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs